Form 4: Centessa Pharmaceuticals Chief Business Officer Sells Shares Under 10b5-1 Plan

Centessa Pharmaceuticals' Chief Business Officer, Gregory M. Weinhoff, sold 11,742 ordinary shares at an average price of $16.4733 per share, as part of a pre-arranged trading plan.

Summary

• Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals, sold 11,742 ordinary shares.
• The sale occurred on January 27, 2025.
• The shares were sold at a weighted average price of $16.4733.
• The sales were executed under a Rule 10b5-1 trading plan adopted on May 22, 2024.
• The price range for the sales was between $16.22 and $16.69 per share.
• Following the transaction, Weinhoff beneficially owns 159,782 ordinary shares.

Sentiment

Score: 5

Explanation: The document reports a routine share sale by an officer under a pre-arranged plan. It is a neutral event with no significant positive or negative implications for the company's outlook.

Industry Context

Sales by company officers are a common occurrence, often under pre-arranged trading plans like Rule 10b5-1, which allows insiders to sell shares without being accused of trading on non-public information. This is a routine transaction and does not necessarily indicate a change in the company's outlook.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a standard practice among publicly traded companies to allow insiders to sell shares without the appearance of insider trading.
• The volume of shares sold by Gregory M. Weinhoff is relatively small compared to the total outstanding shares of Centessa Pharmaceuticals.
• Similar transactions are regularly reported by officers of other pharmaceutical companies such as Pfizer, Moderna, and BioNTech.

Stakeholder Impact

• The share sale has a minimal impact on shareholders as it is a small transaction by an officer under a pre-arranged plan.

Key Dates

Keywords

Centessa Pharmaceuticals, Gregory M. Weinhoff, share sale, Rule 10b5-1, insider trading, CNTA, ordinary shares